ArticleRSC advances2019
A graphene gold nanocomposite-based 5-FU drug and the enhancement of the MCF-7 cell line treatment.
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Bioengineered and biodegradable 3D scaffold for controlled drug delivery of 5-fluorouracil-loaded nanoparticle for bone tumor treatment.Medical oncology (Northwood, London, England) · 2025Article
- Synergistic anticancer effect of Pistacia lentiscus essential oils and 5-Fluorouracil co-loaded onto biodegradable nanofibers against melanoma and breast cancer.Discover nano · 2024Article
- A systematic study on the use of multifunctional nanodiamonds for neuritogenesis and super-resolution imaging.Biomaterials research · 2023Article
- Recent Advances in Nanomaterials of Group XIV Elements of Periodic Table in Breast Cancer Treatment.Pharmaceutics · 2022Review
- Surface-mediated high antioxidant and anti-inflammatory effects of astaxanthin-loaded ultrathin graphene oxide film that inhibits the overproduction of intracellular reactive oxygen species.Biomaterials research · 2022Article
- Binding mechanism and SERS spectra of 5-fluorouracil on gold clusters.Frontiers in chemistry · 2022Article
- The controlled synthesis and DFT investigation of novel (0D)-(3D) ZnS/SiORSC advances · 2021Article
- Enhanced Apoptosis by Functionalized Highly Reduced Graphene Oxide and Gold Nanocomposites in MCF-7 Breast Cancer Cells.ACS omega · 2021Article
- Synthesis, characterization and antimicrobial activity applications of grafted copolymer alginate-RSC advances · 2021Article
- Functionalized Reduced Graphene Oxide as a Versatile Tool for Cancer Therapy.International journal of molecular sciences · 2021Review
- Biogenic synthesis and cytotoxic effects of silver nanoparticles mediated by white rot fungi.Heliyon · 2021Article
- A Simple Route to the Complexation of Lutein with Reduced Graphene Oxide Nanocarriers and Antioxidant Protection Against Blue Light.International journal of nanomedicine · 2021Article
- Advances in nanotechnology and antibacterial properties of biodegradable food packaging materials.RSC advances · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is no doubt that cancer is now one of the most formidable diseases in the world; despite all the efforts and research, common treatment routes, including chemotherapy, photodynamic therapy, and photothermal therapy, suffer from different limitations in terms of their efficiency and performance. For this reason, different strategies are being explored to improve the efficiency of the traditional drugs reported to date. In this study, we have redirected the function of one of these drugs (5-fluorouracil, 5-FU) by combining it with a graphene-gold nanocomposite in different molar ratios that has been exceedingly used for biological research development. The high activity of the graphene-gold material enables it to produce reactive oxygen and ions, which display good anticancer and antioxidant activity through the scavenging of the DPPH, SOD and GP
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.